Oswaldo Cruz Foundation (Fiocruz) is Brazil’s leading public science and technology institution in health. Founded in 1900 and linked to the Ministry of Health, it is headquartered in Rio de Janeiro and operates a nationwide network of research, clinical, and reference laboratories serving the country’s Unified Health System (SUS).
Fiocruz conducts research and innovation in biomedical and public health sciences and produces health technologies at industrial scale. Through units such as Bio-Manguinhos and Farmanguinhos, it develops and manufactures vaccines, biopharmaceuticals, diagnostic kits, and essential medicines, and provides quality control and regulatory reference services. The foundation also supports epidemiological surveillance, delivers specialized healthcare, and offers graduate education and workforce training. Fiocruz collaborates with national and international partners, including multilateral health agencies, to advance access to immunobiologicals and other strategic health products.
None yet. When a new project in the record names Fiocruz as owner, partner or investor, it shows here.
Early, multi-faceted plan includes seven royalty‑free licenses covering 129 LMICs, regional manufacturing support in Africa and Latin America, and early manufacturing investment to speed availability.
QDENGA shows long-term safety and efficacy, reducing dengue cases and hospitalizations. Approved in 41 countries, it remains effective across all virus serotypes with no new safety issues.
